KDR and breast adenocarcinoma: The most promising compound reduceed the cell viability of cancer cell line MCF-7 (breast adenocarcinoma), MDA-MB-231 (breast adenocarcinoma) and Hep G2 (hepatocellular carcinoma) and also suppressed the binding of VEGFR-2 on the surface of VEGF.